Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3201
Gain Therapeutics
GANX
$71.6M
| $169K | ﹤0.01% |
+94,000
| New | +$174K |
2025 Q2
0 quarters
|
|
3202
Urban One Class D
UONEK
$18.1M
| $166K | ﹤0.01% |
26,021
+1,310
| +5% | +$7.84K |
2013 Q2
48 quarters
|
|
|
TAOX
3203
Tao Synergies Inc
TAOX
$28.7M
| $165K | ﹤0.01% |
+21,000
| New | +$59.9K |
2025 Q2
0 quarters
|
|
3204
Rallybio
RLYB
$90.4M
| $164K | ﹤0.01% |
60,629
+11,066
| +22% | +$29.3K |
2024 Q1
5 quarters
|
|
3205
Toro Corp
TORO
$152M
| $164K | ﹤0.01% |
75,000
+7,500
| +11% | +$15.1K |
2023 Q2
8 quarters
|
|
3206
SkinHealth Systems
SKIN
$71.6M
| $163K | ﹤0.01% |
85,591
+20,300
| +31% | +$28.6K |
2024 Q4
2 quarters
|
|
3207
Ebang International Holdings
EBON
$11.5M
| $162K | ﹤0.01% |
49,213
-500
| -1% | -$1.81K |
2021 Q4
14 quarters
|
|
|
LND
3208
BrasilAgro
LND
$377M
| $162K | ﹤0.01% |
42,400
+4,400
| +12% | +$16.8K |
2021 Q4
14 quarters
|
|
3209
American Shared Hospital Services
AMS
$8.78M
| $161K | ﹤0.01% |
66,700
-3,200
| -5% | -$8.29K |
2021 Q3
15 quarters
|
|
|
LFT
3210
Lument Finance Trust
LFT
$27.2M
| $158K | ﹤0.01% |
7,128
-14,882
| -68% | -$375K |
2023 Q2
8 quarters
|
|
|
CODX
3211
Co-Diagnostics
CODX
$7.82M
| $157K | ﹤0.01% |
18,701
+357
| +2% | +$3.34K |
2021 Q2
16 quarters
|
|
|
BTLN
3212
Brightline Interactive
BTLN
$14.6M
| $157K | ﹤0.01% |
14,432
+3,208
| +29% | +$32.8K |
2025 Q1
1 quarter
|
|
|
VSTA
3213
DELISTED
Vasta Platform
VSTA
| $156K | ﹤0.01% |
36,600
+15,500
| +73% | +$67.6K |
2021 Q4
14 quarters
|
|
3214
NanoViricides
NNVC
$33.2M
| $156K | ﹤0.01% |
111,400
+5,600
| +5% | +$7.65K |
2021 Q4
14 quarters
|
|
|
ORKA
3215
Oruka Therapeutics
ORKA
$5.44B
| $156K | ﹤0.01% |
13,900
-21,900
| -61% | -$228K |
2025 Q1
1 quarter
|
|
3216
GrowGeneration
GRWG
$88.4M
| $155K | ﹤0.01% |
166,110
-94,076
| -36% | -$100K |
2024 Q4
2 quarters
|
|
3217
CPS Technologies
CPSH
$68.6M
| $155K | ﹤0.01% |
55,958
+1,000
| +2% | +$2.13K |
2021 Q1
17 quarters
|
|
3218
Cohen & Co
COHN
$34.4M
| $155K | ﹤0.01% |
15,600
-2,731
| -15% | -$22.4K |
2024 Q2
4 quarters
|
|
3219
Harte-Hanks
HHS
$33.2M
| $154K | ﹤0.01% |
38,800
-10,484
| -21% | -$47K |
2022 Q1
13 quarters
|
|
|
NBP
3220
NovaBridge Biosciences American Depositary Shares
NBP
$162M
| $154K | ﹤0.01% |
63,700
-100
| -0.2% | -$136 |
2022 Q3
11 quarters
|
|
|
CMCM
3221
Cheetah Mobile
CMCM
$77M
| $154K | ﹤0.01% |
32,845
-200
| -0.6% | -$806 |
2018 Q4
26 quarters
|
|
3222
SIFCO Industries
SIF
$149M
| $153K | ﹤0.01% |
40,934
-5,762
| -12% | -$17.5K |
2013 Q2
48 quarters
|
|
3223
Broadway Financial
BYFC
$106M
| $153K | ﹤0.01% |
21,049
+200
| +1% | +$1.28K |
2021 Q3
15 quarters
|
|
|
VTYX
3224
DELISTED
Ventyx Biosciences
VTYX
| $153K | ﹤0.01% |
71,300
-945,089
| -93% | -$1.53M |
2024 Q3
3 quarters
|
|
3225
Arts-Way Manufacturing Co
ARTW
$18.4M
| $152K | ﹤0.01% |
66,274
+6,400
| +11% | +$11.2K |
2017 Q1
33 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.